The FDA endorsed a ≥2-point reduction on a visual analogue scale for pain as a clinically meaningful endpoint for urcosimod in NCP. NCP is a chronic ocular pain syndrome with no FDA-approved therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results